Atara Biotherapeutics Inc (NASDAQ:ATRA) has been upgraded to Hold in a report by Zacks Investment Research today.
- Updated: October 10, 2016
Just yesterday Atara Biotherapeutics Inc (NASDAQ:ATRA) traded 6.81% higher at $18.50. Atara Biotherapeutics Inc’s 50-day average is $20.16 and its two hundred day average is $20.32. With the last stock price down -8.97% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 125,724 shares of the stock were exchanged, down from an average trading volume of 168,602
Zacks Investment Research has upgraded Atara Biotherapeutics Inc (NASDAQ:ATRA) to Hold in a statement released on Monday October 10, 2016.
See Chart Below
Atara Biotherapeutics Inc has a with a one year low of $13.31 and a one year high of $40.80 ATRA’s total market value is presently $0.
A total of 5 firms have issued a report on the stock. Three brokerages rating the stock a strong buy, 1 analyst rating the company a buy, 1 broker rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 1 firm rating the company a sell with a 12-month price target of $28.60.
Brief Synopsis About Atara Biotherapeutics Inc (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.